At this page, you can read the short CV’s of the speakers at our Annual Conference (once received, in alphabetical order of the first name).

    Alan Thompson is Dean of the Faculty of Brain Sciences at University College London and Consultant Neurologist at the National Hospital for Neurology and Neurosurgery at Queen Square, London.

Prof. Thompson’s main area of expertise is in particular the diagnosis, evaluation, and management of multiple sclerosis.

Prof. Thompson is chair of the Scientific Committee of the International Progressive MS Alliance and Editor-in-Chief for Multiple Sclerosis Journal.

    Dominik Tomek served for many years in the Drug Committee of State Institute for Drug Control, Pricing Committee of Ministry of Finance and Reimbursement Committee of Ministry of Health, Slovak Agency for Health Technology Assessment, SLOVAHTA. He is teaching at the Faculty of Medicine, Slovak medical university, Bratislava, Slovakia.

He is collaborating with Ministry of Health in Slovakia in the field of horizon scanning of incoming drugs and other health technologies and in the ministerial legislative working group for drug reimbursement. He is the chairman of the EUPATI Slovakia National Platform and Fit for Work Slovakia National Platform.

In the recent years he performed several projects in the field of patients reported outcome studies, e. g. autoimmune diseases, asthma and COPD, metastatic melanoma.

    Harriet Doig graduated from King’s College London in 2005 and also completed a Social Science degree from Dublin Business School. She just completed a Masters in Rehabilitation and Disability Studies at University College Dublin.

She worked in a variety of information provision and advocacy roles in the voluntary sector, in the United Kingdom and Ireland.

Harriet has worked at MS Ireland as Information, Advocacy and Research Officer since 27th October 2015. Her role includes producing new MS Ireland publications, maintaining up-to-date information resources, lobbying and advocacy, and promoting and supporting the MS Ireland research agenda.

    Hartmut Wekerle was director and member of the Max Planck Institute of Neurobiology. In 2012 he was awarded a Hertie Senior Professorship, and he leads an Extended Emeritus Group.

Hartmut Wekerle’s scientific research focuses on the mechanisms initiating and driving multiple sclerosis and its experimental models, which imply autoimmune attack against the nervous system.

Wekerle’s work led to the identification of brain reactive autoimmune T lymphocytes in the immune system. Most recently, he identified the commensal bacterial gut flora as a factor triggering the pathogenic potential of immune cells.

    Lars Alfredsson is professor of Epidemiology at the Institute of Environmental Medicine, Karolinska Institutet.

Prof Alfredsson mainly carried out research with the aim of identifying causes of cardiovascular and inflammatory diseases, especially rheumatiod arthrits and multiple sclerosis, and also been working in the field of pharmaco-epidemiology.

Member Board of Postgraduate education at Karolinska Institutet, 2012-2015; Member Board of Swedish Research Council for Health, Working Life and Welfare (FORTE) 2013-

    Marleen Verbeeck is a clinical research professional since 1995. Since 2004 she works at the European Centre for Clinical Research Training and trains staff from the pharmaceutical and medical device industry, as well as non-profit organisations.

She is author of scientific papers, clinical trial study protocols and final study reports. Her experience in medical areas include gastroenterology, central nervous system, rheumatology, oncology and immunotherapy.

    Tobias Derfuss is a clinical neurologist with a specialisation in neuroimmunology.

Since 2010 he is professor and senior physician at the Department of Neurology and the Department of Biomedicine at the university clinic in Basel.

His main research focus is the discovery of biomarkers and analyzing the mode of action of disease modifying treatments in MS. Especially the role of B cells in the pathogenesis of MS and the interaction of B cells with their target cells is explored in cell culture as well as in in vivo models.

Dr. Derfuss is also involved in the design and conduct of clinical trials for newly emerging therapies in MS and is Treasurer of ECTRIMS.